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Cannabidiol eFigure 1. Effect of ⌬9-tetrahydrocannabinol and cannabidiol on negative symptoms, general psychopathologic conditions, and Positive and Negative Symptom Scale (PANSS) total score over time. Plots showing changes in negative symptoms as indexed by PANSS negative symptom subscale score (A), general psychopathologic conditions as indexed by PANSS general psychopathologic subscale score (B), and total PANSS score (C) under the effect of ⌬9-tetrahydrocannabinol (square), cannabidiol (triangle), and placebo (circle) over time (x-axis). Error bars show SEM. ⌬9-Tetrahydrocannabinol caused significant increase in PANSS negative symptom and PANSS general psychopathologic ratings and total PANSS score (PϽ.01, repeated-measures analysis of variance), while there was no significant effect of cannabidiol on any of these measures. Drug capsules were given soon after obtaining baseline measures, and subsequent ratings were obtained after 1, 2, and 3 hours. There was no statistically significant effect of session order or drugϫsession-order interaction on behavioral symptoms. 
